www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products advises of HIV treatment benefits of ImmunoXel in USA Study
Pharmaceutical and Healthcare group, Stirling Products (ASX:STI) has advised the in vitro and in vivo laboratory studies that commenced in 2009 in the USA at a major national US research institute have resulted in a positive determination of certain mechanisms of action of ImmunoXel and opened up potentially new opportunities for its clinical use.
New findings that emerged from these studies now indicate that:
- ImmunoXel did not show any sign of toxicity in the in vitro studies on the peripheral blood mononuclear cells from Rh-macaques in advanced stage of SIV-disease. This finding further supports all the previous clinical data demonstrating the safety of ImmunoXel in patients with HIV and TB.
- ImmunoXel increases the production of cytokine IL2 and proliferation marker K167 in response to exposure to a viral antigen (SIVenv peptides) in vitro in T-cells from chronically SIV-infected monkeys. This could be one of the mechanisms supporting the restoration of depleted CD4 cell counts in patients
with HIV/AIDS.
- ImmunoXel amplifies the in vitro vaccine-specific T-cell proliferation response in a monkey model of HIV vaccination.
Preliminary results from this study indicate the specific profile of ImmunoXel’s immunomodulation that results in its clinical efficacy. First, ImmunoXel restores the ability of T-cells in chronic disease to proliferate, as demonstrated in a chronic HIV model in macaque monkeys. Second, ImmunoXel amplifies antigen-specific immune response in a HIV vaccine model in rhesus monkeys.
Stirling Products managing director, Peter Boonen said: “We are very pleased with the results of these studies which were initiated independently to the Company through one of the world’s leading research institutes in the USA."
"The continuing studies are designed to better understand the ImmunoXel structural, molecular and cellular mechanics. The preliminary study results provided to us strongly support the use of ImmunoXel in the treatment of HIV, and possibly as an adjuvant to certain HIV vaccines under development. This is a particularly important finding as the successful treatment of HIV still currently represents a major unmet challenge with over 35 million people globally living with the condition, he said."
"The situation with TB is equally as urgent and to our knowledge there is no other product development in
either the treatment of HIV or TB that has demonstrated the profile of efficacy that ImmunoXel demonstrates comparative to current treatment regimes.”
